Zachary E. Freedman

As a corporate associate at Olshan, Zachary E. Freedman engages in securities and general corporate transactions, focusing on securities offerings and M&A transactions.

Zach handles a variety of corporate matters. Zach has experience assisting companies in connection with initial public offerings, secondary offerings, regulatory compliance and corporate governance. Zach also assists publicly traded and privately held companies with mergers and acquisitions, financing transactions and other commercial transactions. 

Zach was an academic intern in the Real Estate Law Department at Olshan in 2020. He received his J.D. from New York Law School and holds a B.A. from Syracuse University.

• Represented Jeffrey R. Westphal in connection with a $23 million secondary registered block trade offering of shares of Class A common stock of Vertex, Inc. (Nasdaq: VERX), underwritten by Goldman Sachs & Co. LLC.
• Represented Blink Charging Co. (Nasdaq: BLNK) in connection with its $250 million ATM offering of its common stock with six investment banking firms, Barclays Capital Inc., BofA Securities, Inc., HSBC Securities (USA) Inc., ThinkEquity LLC, H.C. Wainwright & Co., LLC and Roth Capital Partners, LLC.
• Represented ImmunityBio, Inc. (Nasdaq: IBRX) in its approximately $40 million acquisition of a leasehold interest in a pharmaceutical manufacturing space in western New York and certain related assets from Athenex, Inc. (Nasdaq: ATNX).
• Represented Ault Disruptive Technologies Corporation (NYSE American: ADRT) in its $115 million initial public offering.
• Represented a hedge fund in connection with an approximately $640 million underwritten secondary offering and concurrent share repurchase.
• Represented Kaufman Astoria Studios in the sale of the historic, century old studios to the joint venture of Hackman Capital Partners and Square Mile Capital Management.
• Represented P10, Inc. (NYSE: PX) in its $240 million initial public offering of shares of its Class A common stock.
• Represented Alleghany Corporation in its $500 million public offering of 3.250% Senior Notes.
• Represented Alzamend Neuro, Inc. (Nasdaq: ALZN) in its $14.4 million initial public offering of shares of its common stock.
• Represented Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) in its $21 million initial public offering of shares of its common stock.

Press Releases